公开(公告)号：EP1626707A2

公开(公告)日：2006-02-22

申请号：EP04708594.9

申请日：2004-02-05

申请人： Teva Pharmaceutical Industries Limited

发明人： LICHT, Daniella ,  LOVINGER, Ioana ,  ABD-ELHAI, Suher ,  DAGAN-LION, Mazzi ,  GILBERT, Adrian ,  LEIBOVITCH, Noa ,  COHEN, Sasson ,  LEVY, Ruth

IPC分类号： A61K9/20

CPC分类号： A61K31/16 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K31/19

摘要： The subject provides a sustained release tablet comprising the following components: a) a uniform admixture of an active ingredient selected from the group consisting of valproic sodium acid, a pharmaceutically acceptable salt or ester of valproic acid, divalproex sodium, valpromide and a compound having the structure of formula (I) or formula (II), wherein R1, R2, and R3 are independently the same or different and are hydrogen, a C1-C6 alkyl group, an aralkyl group, or an aryl group, and n is an integer which is greater than or equal to 0 and less than or equal to 3; and a binder, and b) a hydroxypropylmethyl cellulose, a process for manufacturing the tablet and a method of treating neuropathic pain, epilepsy, mania in bipolar disorder, a headache disorder, pain or of effecting pain prophylaxis in a subject.